

\*\*\*\*Published November 2013\*\*\*\*

## MarketVIEW: Chagas disease vaccines

<b>Product Name</b>	:	<b>MarketVIEW: Chagas disease vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation + 1 forecast model
<b>Therapeutic Area</b>	:	Pediatric/endemic vaccines
<b>Publication date</b>	:	November 2013
<b>Catalogue No</b>	:	VAMV051

## Background

**Chagas disease**, is caused by the protozoan parasite *Trypanosoma cruzi* (*T.cruzi*). *T.cruzi* mainly infects young children living in poverty and it is estimated that around 10 million people carry the pathogen with 99% living in Latin America. After acute infection most individuals remain in an asymptomatic indeterminate disease phase, which can last for decades. However, around 30 to 40% progress to chronic disease (determinate phase) , which includes serious cardiac and gastrointestinal manifestations. It is estimated that around 10,000 deaths occur each year due to chronic Chagas disease with substantial economic losses.

Although antiparasitic drugs have proven efficacy against Chagas disease in the early stages, their effectiveness in established chronic disease is very low. For this reason investigators are pursuing *T.cruzi* vaccine approaches which may prevent infection or treat infection after exposure. For the latter, a vaccine may decrease parasite load below a threshold which reduces disease severity and/or delays complications. The **Sabin Vaccine partnership** are currently progressing preclinical *T.cruzi* vaccine candidate (Tc24/TSA-1).

This **MarketVIEW** product is a comprehensive commercial opportunity assessment detailing the potential for *T.cruzi* vaccine profiles in the LATAM, US and EU regions. Two therapeutic vaccine profiles (TX) are modelled in determinate and indeterminate populations to 2034 , along with investigation also of a prophylactic (PX) vaccine profile. The analysis provides an up-to-date review of the literature in terms of epidemiology, treatment, cost implications coupled with a review of vaccine development history to date. Clear assumptions are provided in terms of prospective vaccine launch date, penetration estimates, pricing estimates and gross revenue forecasts.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Chagas disease vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of pediatric vaccines has also been utilised. **\*\*\*See Bibliography for exact sources.**

### PRODUCT CONTENTS:

**Published November 2013 (CAT No: VAMV051)**

\*\*\*\*This product is composed of a model and summary presentation

#### Contents – Summary presentation (MS PowerPoint based)

Author's note  
Executive Summary  
T.cruzi therapeutic vaccine: potential revenues to 2034 per scenario  
T.cruzi therapeutic vaccine: potential volumes to 2034 per scenario  
T.cruzi therapeutic vaccine: potential revenues to 2034 per region LO  
T.cruzi therapeutic vaccine: potential revenues to 2034 per region HI  
T.cruzi prophylatic vaccine: potential revenues to 2034 per scenario  
T.cruzi prophylatic vaccine: potential volumes to 2034 per scenario  
T.cruzi therapeutic vaccine: sensitivity analysis  
Chagas disease: Disease background and epidemiology  
Chagas disease: introduction  
Trypanosoma cruzi: geographical distribution  
Trypanosoma cruzi: distribution of cases of infection 2006-2009  
Chagas disease: prevalence (major countries)  
Trypanosoma cruzi: endemic zones  
Chagas disease: infected individuals, DALYS  
Chagas disease: overall morbidity & mortality  
The parasite: Trypanosoma cruzi  
Natural history of Chagas disease  
Trypanosoma cruzi: life-cycle  
Trypanosoma cruzi: vectors  
Trypanosoma cruzi: major triatomine species  
Trypanosoma cruzi: hosts  
Trypanosoma cruzi: variables influencing human infection  
Trypanosoma cruzi: other modes of transmission  
Trypanosoma cruzi: summary of transmission routes  
Chagas disease: country groupings and disease characteristics  
Trypanosoma cruzi: vector control  
Trypanosoma cruzi: impact of immigration  
Trypanosoma cruzi: United States  
Trypanosoma cruzi: immigrants to selected EU countries1  
Chagas disease: clinical aspects

**Continued.....**

Chagas disease: diagnosis  
Chagas disease: flowchart  
Chagas disease: clinical aspects - acute phase  
Chagas disease: clinical aspects - indeterminate/chronic phase  
Chagas disease: cardiac form  
Chagas heart disease  
Chagas disease: digestive form  
Chagas disease: clinical forms and age groups  
Chagas disease: current treatment  
Chagas disease treatments: cost of therapy  
Chagas disease: vaccine development  
Trypanosoma cruzi: immune response  
Trypanosoma cruzi: an autoimmune phenomena?  
Trypanosoma cruzi: rationale for vaccine development  
Trypanosoma cruzi: stages for vaccine development  
Desirable immune responses of a Trypanosoma cruzi vaccine  
Trypanosoma cruzi: vaccine development history  
Trypanosoma cruzi vaccines: preclinical subunit approaches  
Trypanosoma cruzi: DNA vaccine approaches  
Trypanosoma cruzi: therapeutic vaccination background  
Performance of TSA-1 and Tc24 antigens  
T. cruzi therapeutic vaccine initiative: Sabin PDP  
T. cruzi therapeutic vaccine initiative: partners  
T. cruzi therapeutic vaccine initiative: activities  
T. cruzi therapeutic vaccine initiative: roles/responsibilities  
Trypanosoma cruzi vaccine(s): developmental challenges  
Trypanosoma cruzi vaccines: TcVAC-3  
Chagas disease: overall research priorities  
Chagas disease: research into new treatments  
T.cruzi therapeutic vaccine: modelling commercial potential  
T.cruzi therapeutic vaccine: modelling strategy  
T.cruzi therapeutic vaccine: target product profile (TPP) – LO  
T.cruzi therapeutic vaccine: target product profile (TPP) – HI  
T.cruzi therapeutic vaccine: modelling scenarios  
TX Modelling strategy: populations/target groups/presentation  
TX Modelling strategy: product penetration/introduction  
T.cruzi therapeutic vaccine: penetration rates chosen  
T.cruzi therapeutic vaccine: compliance/boosting rates chosen  
Trypanosoma cruzi vaccines: cost effectiveness  
T.cruzi therapeutic vaccine: pricing estimates used in model  
T.cruzi prophylactic vaccine: modelling commercial potential  
T.cruzi prophylactic vaccine: target product profile (TPP)  
T.Cruzi prophylactic vaccine: modelling strategy  
Disclaimer  
About **VacZine Analytics**

**PAGES: 100 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form**

**Continued.....**

**Contents – Vaccine demand model(s) (MS Excel-based) – 1 model**

Title sheet  
Prophylactic vaccine→  
PX charts – VOL VAL  
All LATAM (PX)  
Therapeutic vaccine→  
TX charts – VOL  
TX charts – VAL  
Grand scenario summary – TX  
Val sum Hi scenario  
Val sum Lo scenario  
Global price summary  
Vol sum Hi scenario  
Vol sum Lo scenario  
Country worksheets→  
USA LO  
USA HI  
Canada low  
Canada hi,  
Mexico low  
Mexico hi,  
El Salvador low  
El Salvador hi,  
Honduras low  
Honduras hi  
Guatemala low  
Guatemala low  
Nicaragua low  
Nicaragua hi  
Argentina lo  
Argentina hi,  
Bolivia low  
Bolivia hi,  
Brazil low  
Brazil hi,  
Chile low  
Chile hi,  
Colombia low  
Colombia high  
Ecuador low  
Ecuador hi,  
Paraguay low  
Paraguay hi,  
Peru low  
Peru hi,  
Venezuela low  
Venezuela hi,

**Continued.....**



Other LATAM low  
Other LATAM hi,  
EU low  
EU high  
Source material  
T. Cruzi prevalence  
EU immigration  
Population >2 yrs  
Population >14 yrs

**WORKSHEETS: ~56**

## PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8995.00**/ GBP **£5800.00**<sup>#</sup> (Region license)\*
- PRESENTATION OR MODEL ONLY - USD **\$4995.00** (Region license)\*

<sup>#</sup> Indicative rate only. Prevailing rate applied to date of transaction.


\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY:

1. Kirchhoff LV et al. Epidemiology of American trypanosomiasis. 2011. *Advances in Parasitology*, Volume 75.
2. Bern C et al. Acute and Congenital Chagas Disease. 2011. *Advances in Parasitology*, Volume 75.
3. Rassi, A., Jr., Rassi, A., Marin-Neto, J.A., 2010. Chagas disease. *Lancet* 375, 1388–1402.
4. WHO First WHO report on neglected tropical diseases. Working to overcome the global impact of neglected tropical diseases. Available at: [http://www.who.int/neglected\\_diseases/2010report/en/](http://www.who.int/neglected_diseases/2010report/en/). Accessed September 2013
5. Araujo A et al. Paleoparasitology of Chagas disease – a review. *Memórias do Instituto Oswaldo Cruz*, 2009, 104(Suppl. I):S9–S16.
6. Schmunis GA. Epidemiology of Chagas disease in non endemic countries: the role of international migration. *Memórias do Instituto Oswaldo Cruz*, 2007, 102(Suppl. 1):S75–S85.
7. Bioventures for global health. Chagas disease. Available at: <http://www.bvgh.org/Biopharmaceutical-Solutions/Global-Health-Primer/Diseases/cid/ViewDetails/ItemID/1.aspx#burden> Accessed September 2013
8. Ramos-Ligonio A, López-Monteon A, Guzmán-Gómez D, Rosales-Encina JL, Limón-Flores Y, Dumonteil E. Identification of a hyperendemic area for *Trypanosoma cruzi* infection in central Veracruz, Mexico. *Am. J. Trop. Med. Hyg.* 83(1), 164–170(2010).
9. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. *PLoS Negl. Trop. Dis.* 2(9), e300(2008).
10. Rassi A, Jr, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. *New England Journal of Medicine*, 2006, 355:799–808
11. Mendez GF, Cowie MR (2001) The epidemiological features of heart failure in developing countries: a review of the literature. *Int J Cardiol* 80: 213–219
12. Chagas C. Nova tripanozomíase humana. Estudos sobre a morfologia e o ciclo evolutivo do *Schizotrypanum cruzi* n. gen., n. sp., agente etiológico de nova entidade mórbida do homem. *Mem Inst Oswaldo Cruz.* 1909;1:159-218.
13. Kirchhoff LV et al. Chagas disease. Medscape. Available at: <http://emedicine.medscape.com/article/214581-overview>. Accessed September 2013
14. Coura JR et al. Chagas disease: 100 years after its discovery. A systemic review. *Acta Tropica.* 115 (2010) 5-13
15. US Centres for Disease Control and Prevention. Chagas disease. Available at: <http://www.cdc.gov/parasites/chagas/biology.html>. Accessed September 2013
16. Lent H, Wygodzinsky P. Revision of the Triatominae (Hemiptera, Reduviidae), and their significance as vectors of Chagas' disease. *Bull Am Museum Natural History.* 1979;163:123-520.
17. WHO Expert Committee. 2002. Control of Chagas disease. WHO technical report series number 905. World Health Organization, Geneva, Switzerland
18. Pan American Health Organization. 2010, posting date. Chagas disease (American trypanosomiasis). <http://www.paho.org/english/ad/dpc/cd/chagas.htm>.
19. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. *Clin Microbiol Rev.* Jan 2005;18(1):12-29
20. US Centers for Disease Control and Prevention. Blood Donor Screening for Chagas Disease --- United States, 2006—2007. February 23, 2007 / 56(07);141-143
21. Barcan L, Luna C, Lunao C, et al. Transmission of *T. cruzi* infection via liver transplantation to a nonreactive recipient for Chagas' disease. *Liver Transpl.* Sep 2005;11(9):1112-6. [Medline].
22. Centers for Disease Control and Prevention. Chagas disease after organ transplantation--United States, 2001. *MMWR Morb Mortal Wkly Rep.* Mar 15 2002;51(10):210-2. [Medline].
23. Gürtler RE, Segura EL, Cohen JE. Congenital transmission of *Trypanosoma cruzi* infection in Argentina. *Emerg Infect Dis.* Jan 2003;9(1):29-32.
24. Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. *J Antimicrob Chemother.* Sep 2003;52(3):441-9.
25. Di Primio, R. An outbreak of illness in Teutonia. *Trop.Dis.Bull.* Ref Type: Abstract. 1968;65(4):400-401.
26. Shikanai-Yasuda MA, Marcondes CB, Guedes LA, et al. Possible oral transmission of acute Chagas' disease in Brazil. *Rev Inst Med Trop Sao Paulo.* Sep-Oct 1991;33(5):351-7. [Medline].
27. Steindel M, Kramer Pacheco L, Scholl D, et al. Characterization of *Trypanosoma cruzi* isolated from humans, vectors, and animal reservoirs following an outbreak of acute human Chagas disease in Santa Catarina State, Brazil. *Diagn Microbiol Infect Dis.* Jan 2008;60(1):25-32. [Medline].
28. Beltrao, B., Cerroni, P., Freitas, D.R., Pinto, A.Y., Valente, C., Valente, S.A., et al., 2009. Investigation of two outbreaks of suspected oral transmission of acute Chagas disease in the Amazon region, Para State, Brazil, in 2007. *Trop. Doct.* 39, 231–232.
29. Santos FC, Amato N, V, Gakiya E, et al. Microwave treatment of human milk to prevent transmission of Chagas disease. *Rev Inst Med Trop Sao Paulo.* 2003;45:41-42.
30. Dias, J.C.P et al. Clínica e terapêutica da doença de Chagas. Um manual prático para o clínico geral. Editora Fiocruz, Rio de Janeiro, pp. 33-66.

31. Carlier, Y et al. 2002. Trypanosomiase Americaine ou maladie de Chagas. Enciclop. Med. Chirurg 8, 505–520.
32. Dias, J.C.P., Macedo, V.O., 2005. Doenc, a de Chagas. In: Coura, J.R. (Ed.), Dinâmica das Doenc, as Infecciosas e Parasitárias. Editora Guanabara Koogan, Rio de Janeiro, pp. 557–593
33. Schmunis, G.A., 2007. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem. Inst. Oswaldo Cruz 102 (Suppl. I), 75–85.
34. Coura, J.R., Dias, J.C.P., 2009. Epidemiology, control and surveillance of Chags disease—100 years after its discovery. Mem. Inst. Oswaldo Cruz 104 (Suppl. I), 31–40.
35. Dias JCP et al (1999) The evolution of Chagas disease (American trypanosomiasis) control after 90 years since Carlos Chagas discovery. Mem Inst Oswaldo Cruz 94: 103–121.
36. Silveira AC [ed.] (2002) El control de la enfermedad de Chagas en los países del Cono Sur de América. Historia de una iniciativa internacional. 1991/2001. Uberaba: Facultad de Medicina, Pan American Health Organization.
37. World Health Organization (2007) Reporte sobre la enfermedad de Chagas. TDR/SWG/09. Geneva: WHO
38. Schmunis GA et al. Chagas disease: A Latin American health problem becoming a world health problem. Acta Tropica 115 (2010) 14–21
39. Bern, C., Montgomery, S.P., 2009. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49 (5), e52–e54
40. Chin-Hong, P.V. Et al 2011. Screening and Treatment of Chagas Disease in Organ Transplant Recipients in the United States: Recommendations from the Chagas in Transplant Working Group. American Journal of Transplantation. 11, 672–680.
41. Schijman, A.G., Altcheh, J., Burgos, J.M., Biancardi, M., Bisio, M., Levin, M.J., et al., 2003. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. J. Antimicrob. Chemother. 52, 441–449.
42. Rassi A et al. Circulation 2007;115:1101-1108
43. Rassi A et al. American Trypanosomiasis (Chagas disease). Infect Dis Clin Am 26 (2012) 275-291
44. Nunes MCP et al. Chagas disease. An overview of clinical and epidemiological aspects. J Amer Col Cardio. Vol 62, 9, 2013
45. Andrade JP, Marin Neto JA, Paola AA, et al. I Latin American Guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary. Arq Bras Cardiol 2011;96:434–42.
46. Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol 2001;76:75–96.
47. Rassi A, Rezende JM, Luquetti AO, et al. Clinical phases and forms of Chagas disease. In: Telleria J, Tibayrenc M, editors. American trypanosomiasis (Chagas disease). One hundred years of research. 1st edition. Burlington (MA): Elsevier Inc; 2010. p. 709–41..
48. Coura, J.R., Anunziato, N., Willcox, H.P.F., 1983. Morbidade da doenc, a de Chagas. I. Estudo de casos procedentes de vários estados do Brasil, observados no Rio de Janeiro. Mem. Inst. Oswaldo Cruz 78, 362–372.
49. Levy M et al. Targeted Screening Strategies to Detect Trypanosoma cruzi Infection in Children. PLOS. 2007
50. REFS within: Coura, J.R., de Castro, S.L., 2002. A critical review on Chagas disease chemotherapy. Mem.Inst. Oswaldo Cruz 97, 3–24.
51. Ribeiro I, Sevcsik AM, Alves F, Diap G, Don R, et al. (2009) New, improved treatments for chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 3: e484
52. Castillo-Riquelme M, Guhl F, Turriago B et al. The costs of preventing and treating chagas disease in Colombia. PLoS Negl. Trop. Dis. 2(11), e336(2008)
53. Vallejo M, Montenegro P, Reyes PA. How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital. Arch. Cardiol. Mex. 72(2), 129–137(2002).
54. Samudio, M., Montenegro-James, S., Cabral, M., Martinez, J., Rojas de Arias, A., James, M.A., 1998. Cytokine responses in Trypanosoma cruzi-infected children in Paraguay. Am. J. Trop. Med. Hyg. 58, 119–121.
55. Moretti, E., Basso, B., Cervetta, L., Brigada, A., Barbieri, G., 2002. Patterns of cytokines and soluble cellular receptors in the sera of children with acute Chagas' disease. Clin. Diagn. Lab. Immunol. 9, 1324–1327.
56. Cunha-Neto, E., Duranti, M., et al., 1995. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. Proc. Natl. Acad. Sci. U.S.A. 92 (8), 3541–3545.
57. Refs within: Urbina JA et al. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Tropica 115 (2010) 568
58. Kaplan, D., Vazquez, M., et al., 1993. The chronic presence of the parasite, and anti-P autoimmunity in Chagas disease: the Trypanosoma cruzi ribosomal P proteins, and their recognition by the host immune system. Biol. Res. 26 (1–2), 273–277
59. Cunha-Neto, E., Duranti, M., et al., 1995. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. Proc. Natl. Acad. Sci. U.S.A. 92 (8), 3541–3545
60. Machado FS, Tyler KM, Brant F, Esper L, Teixeira MM, Tanowitz HB. Pathogenesis of Chagas disease: time to move on. Front. Biosci. (Elite Ed.) 4, 1743–1758(2012).
61. Vazquez-Chagoyan et al. Vaccine Development Against Trypanosoma cruzi and Chagas Disease. Advances in Parasitology, Volume 75.



62. Dumonteil E et al. Vaccine development against *Trypanosoma cruzi* and *Leishmania* species in the post-genomic era. *Infection, Genetics and Evolution* 9 (2009) 1075–1082
63. Dumonteil E (2007) DNA Vaccines against Protozoan Parasites: Advances and Challenges. *J Biomed Biotechnol* 2007: 90520. doi: 10.1155/2007/90520
64. B.Wizel, M.Nunes, and R. L. Tarleton, "Identification of *Trypanosoma cruzi* trans-sialidase family members as targets of protective CD8+ TC1 responses," *The Journal of Immunology*, vol. 159, no. 12, pp. 6120–6130, 1997.
65. Quijano-Hernandez IA, Bolio-González ME, Rodríguez-Buenfil JC, Ramirez-Sierra MJ, Dumonteil E. Therapeutic DNA vaccine against *Trypanosoma cruzi* infection in dogs. *Ann. NY Acad. Sci.* 1149, 343–346(2008).
66. Dumonteil E et al. Accelerating the Development of a Therapeutic Vaccine for Human Chagas Disease. Rationale and Prospects. *Expert Rev Vaccines*. 2012;11(9):1043-1055.
67. Sabin Vaccine Institute. Chagas Disease Vaccine. Available at: <http://www.sabin.org/programs/chagas-diseaseleishmaniasis/chagas-disease-vaccine>. Accessed September 2013
68. Gupta S et al. TcVac3 Induced Control of *Trypanosoma cruzi* Infection and Chronic Myocarditis in Mice. *PLOS one*. Published: Mar 26, 2013  
DOI: 10.1371/journal.pone.0059434
69. Coura, J.R., 2007. Chagas disease: what is known and what is needed. A background article. *Mem. Inst. Oswaldo Cruz* 102 (Suppl. I), 113–122.
70. US Census Bureau. International Database (IDB). Available at: <http://www.census.gov/ipc/www/idb/index.php>. Accessed August 2013
71. Organización Panamericana de la Salud. 2006. Estimación cuantitativa de la enfermedad de Chagas en las Americas OPS/HDM/CD/425-06. Organización Panamericana de la Salud, Washington, DC
72. Ribeiro AL, Rocha MO. [Indeterminate form of Chagas disease: considerations about diagnosis and prognosis]. *Rev Soc Bras Med Trop* 1998;31:301–14.
73. Dias JC. The indeterminate form of human chronic Chagas' disease A clinical epidemiological review. *Rev Soc Bras Med Trop* 1989;22: 147–56.
74. Sabino EC, Ribeiro AL, Salemi VM, et al. Ten-year incidence of Chagas cardiomyopathy among asymptomatic *Trypanosoma cruzi* seropositive former blood donors. *Circulation* 2013;127:1105–15.
75. Castillo-Riquelme M, Guhl F, Turriago B et al. The costs of preventing and treating chagas disease in Colombia. *PLoS Negl. Trop. Dis.* 2(11), e336(2008)
76. Manne JM et al Barriers to Treatment Access for Chagas Disease in Mexico *PLOS* 2013
77. Rassi A et al Heart Disease in Latin America. Predictors of Mortality in Chronic Chagas Disease. A Systematic Review of Observational Studies. *Circulation*. 2007; 115: 1101-1108.
78. Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR (2010) The Potential Economic Value of a *Trypanosoma cruzi* (Chagas Disease) Vaccine in Latin America. *PLoS Negl Trop Dis* 4(12): e916. doi:10.1371/journal.pntd.0000916

## TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

### VacZine Analytics

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009

Signup to our newsletter ExpertREACT - <http://www.vacZine-analytics.com/products-expertreact.asp>



Follow us on Twitter @vaczineanalytic